Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Reardon

Showing results (61-70 of 404) with videos related to

Pageof 41
Sort By:
Annual Review of Cancer Biology|February 7, 2024
The Blood-Brain Barrier: Implications for Experimental Cancer TherapeuticsJoelle P Straehla, David A Reardon, Patrick Y Wen, et al.
Hematology/Oncology Clinics of North America|November 21, 2021
Is There a Role for Immunotherapy in Central Nervous System Cancers?Catherine Flores, Gavin Dunn, Peter Fecci, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 19, 2024
Cavitation monitoring, treatment strategy, and acoustic simulations of focused ultrasound blood-brain barrier disruption in patients with glioblastomaNathan McDannold, Patrick Y Wen, David A Reardon, et al.
Nuclear Medicine and Biology|October 9, 2007
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodiesMichael R Zalutsky, David A Reardon, Oscar R Pozzi, et al.
Oncology (Williston Park, N.Y.)|June 13, 2003
Irinotecan: promising activity in the treatment of malignant gliomaDavid A Reardon, Henry S Friedman, James B Powell, et al.
Journal of Neuro-Oncology|February 14, 2026
Meta-analysis of treatment-emergent seizures in glioma vaccine trialsLouise Mc Carthy, Brian M Andersen, Patrick Y Wen, et al.
Acta Oncologica (Stockholm, Sweden)|May 11, 2026
A 10-year-long ongoing complete response to vismodegib as first-line treatment in adult metastatic medulloblastomaSuweydo Abdi, Paula Poikonen-Saksela, Päivi Halonen, et al.
Immunotherapy|May 21, 2016
Checkpoint inhibition in meningiomasWenya Linda Bi, Winona W Wu, Sandro Santagata, et al.
Expert Opinion on Biological Therapy|March 21, 2008
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapyDavid A Reardon, Patrick Y Wen, Annick Desjardins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Antiangiogenic therapy for glioblastoma: current status and future prospectsTracy T Batchelor, David A Reardon, John F de Groot, et al.
Pageof 41

Showing results (61-70 of 404) with videos related to

Sort By:
Pageof 41
Annual Review of Cancer Biology|February 7, 2024
The Blood-Brain Barrier: Implications for Experimental Cancer TherapeuticsJoelle P Straehla, David A Reardon, Patrick Y Wen, et al.
Hematology/Oncology Clinics of North America|November 21, 2021
Is There a Role for Immunotherapy in Central Nervous System Cancers?Catherine Flores, Gavin Dunn, Peter Fecci, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|June 19, 2024
Cavitation monitoring, treatment strategy, and acoustic simulations of focused ultrasound blood-brain barrier disruption in patients with glioblastomaNathan McDannold, Patrick Y Wen, David A Reardon, et al.
Nuclear Medicine and Biology|October 9, 2007
Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodiesMichael R Zalutsky, David A Reardon, Oscar R Pozzi, et al.
Oncology (Williston Park, N.Y.)|June 13, 2003
Irinotecan: promising activity in the treatment of malignant gliomaDavid A Reardon, Henry S Friedman, James B Powell, et al.
Journal of Neuro-Oncology|February 14, 2026
Meta-analysis of treatment-emergent seizures in glioma vaccine trialsLouise Mc Carthy, Brian M Andersen, Patrick Y Wen, et al.
Acta Oncologica (Stockholm, Sweden)|May 11, 2026
A 10-year-long ongoing complete response to vismodegib as first-line treatment in adult metastatic medulloblastomaSuweydo Abdi, Paula Poikonen-Saksela, Päivi Halonen, et al.
Immunotherapy|May 21, 2016
Checkpoint inhibition in meningiomasWenya Linda Bi, Winona W Wu, Sandro Santagata, et al.
Expert Opinion on Biological Therapy|March 21, 2008
Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapyDavid A Reardon, Patrick Y Wen, Annick Desjardins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2014
Antiangiogenic therapy for glioblastoma: current status and future prospectsTracy T Batchelor, David A Reardon, John F de Groot, et al.
Pageof 41